<b>Objective:</b> This study aims to engineer a novel nanoparticle formulation for combined tumor therapy, designated as PDA@Mn-siSur-c-NPs, which comprises a polydopamine/manganese dioxide (PDA@MnO<sub>2</sub>) core alongside survivin-targeting siRNA and cyclo(RGD-DPhe-K)-targeting moiety. This evidence concerns the gene BIRC5 and neoplasm.